ASX News

Completion of Phase I Enrolment of Japanese Renal Cancer Study

Tokyo (Japan) – 27th October 2020. Telix Pharmaceuticals Japan K.K. is pleased to announce the completion of Phase I enrolment of the Company’s Phase I/II ZIRDAC-JP study of Telix’s renal cancer diagnostic imaging product TLX250-CDx (89Zr-girentuximab) in Japan.

Telix Pharmaceuticals Japan K.K., a wholly-owned subsidiary of Telix Pharmaceuticals Limited is pleased to announce the completion of Phase I enrolment of the Company’s Phase I/II ZIRDAC-JP study of Telix’s renal cancer diagnostic imaging product TLX250-CDx (89Zr-girentuximab) in Japan.

The ZIRDAC-JP study (Zirconium Dosing and Comparison in Japan) is a Japanese multi-centre Phase I/II study that will recruit approximately 40 patients in total. The objective of the Phase I component of the ZIRDAC-JP study is to comparatively evaluate the safety, tolerability, radiation dosimetry and pharmacokinetics / pharmacodynamics of TLX250-CDx in Japanese patients.

The patient population for the ZIRDAC-JP trial has been selected to be identical to Telix’s global Phase III ZIRCON trial, which is presently recruiting patients at 33 sites internationally and is expected to complete recruitment in Q1 2021. The ZIRDAC-JP study has been designed in consultation with the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) to collect the necessary data to potentially bridge to the ZIRCON study, by confirming that dosing and pharmacology of TLX250-CDx in Japanese patients is equivalent to non-Japanese patients. Following data review and consultation with the PMDA, Telix expects to commence the Phase II component of the ZIRDAC-JP study in early 2021.

Telix Pharmaceuticals Japan K.K. President, Dr. Shintaro Nishimura stated, “The efficient completion of enrolment into the Phase I part of the ZIRDAC-JP study is a testament to the commitment of Dr Nakaigawa, the principal investigator and his team at Yokohama City University Hospital, and most importantly the patients who participated in this trial under COVID-19 conditions.   This represents a significant milestone for Telix Japan and the broader Japanese nuclear medicine community. We now look forward commencing the Phase II part of the ZIRDAC-JP study and ultimately bringing this breakthrough kidney cancer imaging product to market in Japan in coordination with the global development for this asset.

To read the full ASX release please click here.

TLX250-CDx does not have regulatory approval in any jurisdiction.

More Articles

ASX News

Telix New Drug Application for Prostate Cancer Imaging Product Accepted by US FDA

Melbourne (Australia) and Indianapolis, IN (U.S.A.) – 24th November 2020. Telix Pharmaceuticals announces New Drug Application (NDA) for TLX591-CDx (Kit...

ASX News

Telix Presentation at the European Multidisciplinary Congress on Urological Cancers

20th November 2020 | Corporate Spotlight | Recording of Live Presentation at EMUC20 Virtual Congress: New Perspectives in Prostate and...

ASX News

Telix Receives €545,000 Belgian Research Grant for Prostate Cancer Imaging Agent in Europe

Melbourne (Australia) and Liège (Belgium) – 19th November 2020. Advanced Nuclear Medicine Ingredients S.A. (ANMI) announces a €545,000 payment from...

Corporate Spotlight

Telix presentations at European Association of Nuclear Medicine 2020 Satellite Symposium

13th November 2020 | Corporate Spotlight – Recording of live presentations at EANM Virtual Symposium: Next Generation Imaging with PSMA-PET...

ASX News

Investor Briefing: Telix Pharmaceuticals Limited and China Grand Pharma Partnership

Melbourne (Australia) –  3rd November 2020. Telix Pharmaceuticals Provides Investor Briefing: Our Asian Future

ASX News

Telix Pharmaceuticals Limited and China Grand Pharma Announce Strategic Licence and Commercial Partnership for Greater China Market

Melbourne (Australia) and Hong Kong SAR (China) – 2nd November 2020. Telix Pharmaceuticals Limited and China Grand Pharma Announce Strategic...

ASX News

Activity Report and Sales Note to Accompany Appendix 4C

Melbourne (Australia) – 30th October 2020. Telix Pharmaceuticals provides its Activity Report and Appendix 4C for the quarter ending 30th September 2020,...

Corporate Spotlight

Telix Japan to Present at Japanese Society of Nuclear Medicine Annual Scientific Meeting

28th October 2020 – Clinical Spotlight | Telix Japan to Present at Japanese Society of Nuclear Medicine Annual Scientific Meeting

ASX News

Telix Completes Licence Agreement with German Cancer Research Center (DKFZ) for Image-Guided Prostate Surgery

Melbourne (Australia) and Heidelberg, (Germany) – 28th October 2020. Telix has secured an exclusive Intellectual Property licence agreement with the...

ASX News

Completion of Phase I Enrolment of Japanese Renal Cancer Study

Tokyo (Japan) – 27th October 2020. Telix Pharmaceuticals Japan K.K. is pleased to announce the completion of Phase I enrolment...